Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
immunotherapy |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:China
|
| gptkbp:ATCCode |
L01FF10
|
| gptkbp:brand |
gptkb:百泽安
|
| gptkbp:CASNumber |
1801633-27-9
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:BeiGene
|
| https://www.w3.org/2000/01/rdf-schema#label |
tislelizumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
IgG4 monoclonal antibody
|
| gptkbp:mechanismOfAction |
immunotherapy
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:target |
gptkb:PD-1
|
| gptkbp:UNII |
6X9OC3H4WW
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
gptkb:urothelial_carcinoma gptkb:cancer gptkb:classical_Hodgkin_lymphoma |
| gptkbp:bfsParent |
gptkb:programmed_cell_death_protein_1_(PD-1)
|
| gptkbp:bfsLayer |
6
|